Blueprint Medicines announced the European Commission has approved AYVAKYT for thetreatment of adult patients with indolent systemic mastocytosis with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYTis the first and only approved therapy for people living with ISM in Europe.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BPMC:
- Oppenheimer Expects the S&P 500’s Advance to Continue Into 2024 — Here’s Why These 2 Stocks Might Be Worth Buying
- Blueprint Medicines’ AYVAKYT receives positive CHMP opinion
- Roblox upgraded, Bristol Myers downgraded: Wall Street’s top analyst calls
- Blueprint Medicines upgraded to Outperform from Perform at Oppenheimer
- Blueprint Medicines price target raised to $58 from $46 at Barclays
